These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 32488391

  • 1. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
    Reinhorn D, Yerushalmi R, Moore A, Desnoyers A, Saleh RR, Amir E, Goldvaser H.
    Breast Cancer Res Treat; 2020 Jul; 182(2):259-266. PubMed ID: 32488391
    [Abstract] [Full Text] [Related]

  • 2. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
    Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A.
    J Natl Cancer Inst; 2011 Sep 07; 103(17):1299-309. PubMed ID: 21743022
    [Abstract] [Full Text] [Related]

  • 3. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
    Ingle JN.
    Breast; 2013 Aug 07; 22 Suppl 2():S180-3. PubMed ID: 24074784
    [Abstract] [Full Text] [Related]

  • 4. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ.
    Oncology; 2005 Aug 07; 69(1):1-9. PubMed ID: 16088229
    [Abstract] [Full Text] [Related]

  • 5. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT.
    Curr Med Res Opin; 2006 Aug 07; 22(8):1609-21. PubMed ID: 16870085
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
    Rydén L, Heibert Arnlind M, Vitols S, Höistad M, Ahlgren J.
    Breast; 2016 Apr 07; 26():106-14. PubMed ID: 27017249
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
    Qian X, Li Z, Ruan G, Tu C, Ding W.
    Breast Cancer Res Treat; 2020 Jan 07; 179(2):275-285. PubMed ID: 31606823
    [Abstract] [Full Text] [Related]

  • 9. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 10. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
    Chung CT, Carlson RW.
    Clin Breast Cancer; 2004 Sep 10; 5 Suppl 1():S18-23. PubMed ID: 15347435
    [Abstract] [Full Text] [Related]

  • 11. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
    Perez EA.
    Ann Oncol; 2007 Sep 10; 18 Suppl 8():viii26-35. PubMed ID: 17890211
    [Abstract] [Full Text] [Related]

  • 12. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Khosrow-Khavar F, Filion KB, Al-Qurashi S, Torabi N, Bouganim N, Suissa S, Azoulay L.
    Ann Oncol; 2017 Mar 01; 28(3):487-496. PubMed ID: 27998966
    [Abstract] [Full Text] [Related]

  • 13. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
    Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, Amir E.
    J Natl Cancer Inst; 2018 Jan 01; 110(1):. PubMed ID: 28922781
    [Abstract] [Full Text] [Related]

  • 14. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M.
    Clin Ther; 2007 Aug 01; 29(8):1535-47. PubMed ID: 17919537
    [Abstract] [Full Text] [Related]

  • 15. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    Breast International Group (BIG) 1-98 Collaborative GroupSenology Center of Eastern Switzerland, Kantonsspital, St. Gallen, and the Swiss Group for Clinical Cancer Research, Switzerland., Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.
    N Engl J Med; 2005 Dec 29; 353(26):2747-57. PubMed ID: 16382061
    [Abstract] [Full Text] [Related]

  • 16. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
    Buzdar AU.
    Oncologist; 2003 Dec 29; 8(4):335-41. PubMed ID: 12897330
    [Abstract] [Full Text] [Related]

  • 17. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.
    Health Technol Assess; 2007 Jul 29; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
    Carlson RW, Hudis CA, Pritchard KI, National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology, American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors, St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer.
    J Natl Compr Canc Netw; 2006 Nov 29; 4(10):971-9. PubMed ID: 17112447
    [Abstract] [Full Text] [Related]

  • 19. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R.
    Eur J Surg Oncol; 2008 Jul 29; 34(7):746-55. PubMed ID: 18296017
    [Abstract] [Full Text] [Related]

  • 20. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.
    Cancer; 2006 Jun 15; 106(12):2576-82. PubMed ID: 16703595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.